GHK-Cu (Copper Peptide) vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | GHK-Cu (Copper Peptide) | Setmelanotide |
|---|---|---|
| Dose Range | 1 mg–2 mg | 1 mg–3 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |
Key Differences
Unique to GHK-Cu (Copper Peptide):
Unique to Setmelanotide:
Key Studies
GHK-Cu (Copper Peptide)
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Research square, 2026
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.
European journal of pharmacology, 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Aesthetic surgery journal, 2026
Setmelanotide
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.), 2026
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine, 2026
- Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism, 2026
Ready to Learn More?
Looking for trusted sources?